UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number: 000-55008

Zeo ScientifiX, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		47-4180540
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

3321 College Avenue, Suite 246 Davie, FL		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (888) 963-7881

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	☐	Accelerated Filer	☐
Non-Accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 16, 2025, there were 6,449,817 shares of common stock, $0.001 par value per share, issued and outstanding.

ZEO SCIENTIFIX, INC.

TABLE OF CONTENTS

		PAGE NO.
PART I	FINANCIAL INFORMATION

Item 1.	Condensed Unaudited Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	27

Item 4.	Controls and Procedures.	27

PART II	OTHER INFORMATION

Item 1.	Legal Proceedings.	28

Item 1A.	Risk Factors.	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	28

Item 3.	Defaults Upon Senior Securities.	28

Item 4.	Mine Safety Disclosures.	28

Item 5.	Other Information.	28

Item 6.	Exhibits.	28

Signatures		29

Unless stated otherwise, the words “we,” “us,” “our,” the “Company” or “ZEO” in this Quarterly Report on Form 10-Q (this “Report”) refer to Zeo ScientifiX, Inc. (f/k/a Organicell Regenerative Medicine, Inc.), a Nevada corporation, and its subsidiaries.

Cautionary Note Regarding Forward- Looking Statements

The statements contained in this Report that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts. Statements using words such as “may,” “could,” “should,” “expect,” “plan,” “project,” “strategy,” “forecast,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” or similar expressions help identify forward-looking statements.

The forward-looking statements contained in this Report are largely based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur. The Company’s actual results may differ materially from those anticipated, estimated, projected or expected by management.

All forward-looking statements speak only as of the date of this Report. We do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise.

Part I – FINANCIAL INFORMATION

Item 1. Financial Statements

Zeo ScientifiX, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts rounded to the nearest thousand except share amounts)


	April 30, 2025			October 31, 2024
	(Unaudited)
ASSETS
Current Assets
Cash	$	542,000		$	657,000
Accounts receivable, net of allowance for bad debts		11,000			194,000
Other receivables		1,000			3,000
Prepaid expenses		76,000			79,000
Inventories		235,000			232,000
Total Current Assets		865,000			1,165,000

Property and equipment, net		570,000			478,000
TOTAL ASSETS	$	1,435,000		$	1,643,000

LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	1,885,000		$	1,719,000
Finance lease obligations		20,000			5,000
Convertible promissory note, net of debt discount of $33,000 and $45,000		692,000			680,000
Deferred revenue		856,000			884,000
Total Current Liabilities		3,453,000			3,288,000

Long term finance lease obligations		82,000			8,000
Total Liabilities		3,535,000			3,296,000

Commitments and contingencies

Shares Subject To Possible Redemption
Series C Preferred Stock, $0.001 par value, 100 shares authorized; 100 and 100 shares issued and outstanding, respectively		-			-

Stockholders’ Deficit
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 6,344,817 and 6,344,817 shares issued and outstanding, respectively		6,000			6,000
Additional paid-in capital		62,741,000			60,554,000
Accumulated deficit		(64,847,000	)		(62,213,000	)
Total Stockholders’ Deficit		(2,100,000	)		(1,653,000	)

TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ DEFICIT	$	1,435,000		$	1,643,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

Zeo ScientifiX, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts rounded to the nearest thousand except share amounts)

(Unaudited)


	Three Months Ended April 30,						Six Months Ended April 30,
	2025			2024			2025			2024
Revenues (includes sales to related parties of approximately $43,000, $105,000, $75,000, and $169,000, respectively)	$	1,149,000		$	1,131,000		$	2,239,000		$	2,285,000

Cost of revenues		256,000			284,000			447,000			443,000

Gross profit		893,000			847,000			1,792,000			1,842,000

General and administrative expenses		2,287,000			2,411,000			4,439,000			4,568,000

Loss from operations		(1,394,000	)		(1,564,000	)		(2,647,000	)		(2,726,000	)

Other income (expense)
Interest expense		(21,000	)		(20,000	)		(43,000	)		(47,000	)
Other income		24,000			185,000			56,000			334,000

Net loss	$	(1,391,000	)	$	(1,399,000	)	$	(2,634,000	)	$	(2,439,000	)

Net loss per common share - basic and diluted	$	(0.22	)	$	(0.23	)	$	(0.42	)	$	(0.39	)

Weighted average number of common shares outstanding - basic and diluted		6,344,817			6,173,768			6,344,817			6,182,375

The accompanying notes are an integral part of these condensed consolidated financial statements.

Zeo ScientifiX, Inc.

CONDENSED CONSOLIDATED CHANGES TO STOCKHOLDERS’ DEFICIT

For the Three Months and Six Months Ended April 30, 2025 and 2024

(Amounts rounded to the nearest thousand except share amounts)

(Unaudited)

Three Months Ended April 30,


						Additional					Total
	Common Stock					Paid In		Accumulated			Stockholders’
	Shares			Par Value		Capital		Deficit			Deficit
Balance February 1, 2024		6,125,482		$	6,000	$	57,034,000	$	(58,548,000	)	$	(1,508,000	)
Reverse split round-up adjustment		(188	)		-		-		-			-
Cancellation of shares in connection with litigation		(750	)		-		-		-			-
Exchange of accounts payable for stock		20,000			-		20,000		-			20,000
Fair value of equity instruments issued for compensation:
Fair value of vested shares issued		187,875			-		387,000		-			387,000
Fair value of vested options issued		-			-		273,000		-			273,000
Fair value of vested warrants issued		-			-		527,000		-			527,000
Net loss		-			-		-		(1,399,000	)		(1,399,000	)
Balance April 30, 2024		6,332,419		$	6,000	$	58,241,000	$	(59,947,000	)	$	(1,700,000	)

Balance February 1, 2025		6,344,817		$	6,000	$	61,645,000	$	(63,456,000	)	$	(1,805,000	)
Fair value of equity instruments issued for compensation:
Fair value of vested shares issued		-			-		21,000		-			21,000
Fair value of vested options issued		-			-		265,000		-			265,000
Fair value of vested warrants issued		-			-		810,000		-			810,000
Net loss		-			-		-		(1,391,000	)		(1,391,000	)
Balance April 30, 2025		6,344,817		$	6,000	$	62,741,000	$	(64,847,000	)	$	(2,100,000	)

Six Months Ended April 30,

	Common Stock						Additional Paid In		Accumulated			Total Stockholders’
	Shares			Par Value			Capital		Deficit			Deficit
Balance October 31, 2023		7,283,483		$	7,000		$	56,260,000	$	(57,508,000	)	$	(1,241,000	)
Reverse split round-up adjustment		5,803			-			-		-			-
Cancellation of shares in connection with litigation		(1,164,742	)		(1,000	)		1,000		-			-
Exchange of accounts payable for stock		20,000			-			20,000		-			20,000
Fair value of equity instruments issued for compensation:
Fair value of vested shares issued		187,875			-			387,000		-			387,000
Fair value of vested options issued		-			-			519,000		-			519,000
Fair value of vested warrants issued		-			-			1,054,000		-			1,054,000
Net loss		-			-			-		(2,439,000	)		(2,439,000	)
Balance April 30, 2024		6,332,419		$	6,000		$	58,241,000	$	(59,947,000	)	$	(1,700,000	)

Balance October 31, 2024		6,344,817		$	6,000		$	60,554,000	$	(62,213,000	)	$	(1,653,000	)
Fair value of equity instruments issued for compensation:
Fair value of vested shares issued		-			-			53,000		-			53,000
Fair value of vested options issued		-			-			514,000		-			514,000
Fair value of vested warrants issued		-			-			1,620,000		-			1,620,000
Net loss		-			-			-		(2,634,000	)		(2,634,000	)
Balance April 30, 2025		6,344,817		$	6,000		$	62,741,000	$	(64,847,000	)	$	(2,100,000	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Zeo ScientifiX, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts rounded to the nearest thousand except share amounts)

(Unaudited)


	Six Months Ended April 30,
	2025			2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(2,634,000	)	$	(2,439,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		34,000			38,000
Amortization of OID and commitment fee discount – Promissory notes		12,000			12,000
Stock-based compensation		2,187,000			1,960,000
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts		183,000			(42,000	)
Other receivable		2,000			-
Prepaid expenses		3,000			(222,000	)
Inventories		(2,000	)		39,000
Accounts payable and accrued expenses		165,000			(638,000	)
Security deposits		-			7,000
Deferred revenue		(28,000	)		295,000
Net cash used in operating activities		(78,000	)		(990,000	)

CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance leases		(37,000	)		(20,000	)
Net cash used in financing activities		(37,000	)		(20,000	)

Decrease in cash		(115,000	)		(1,010,000	)
Cash at beginning of period		657,000			1,756,000
Cash at end of period	$	542,000		$	746,000

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes	$	-		$	-
Cash paid for interest	$	-		$	-

NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Reduction in accounts payable for equipment returned to vendor	$	-		$	21,000
Exchange of shares for payables	$	-		$	20,000
Finance lease obligations	$	125,000		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Zeo ScientifiX, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS AND SIX MONTHS PERIODS ENDED APRIL 30, 2025 AND 2024

(UNAUDITED)

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Zeo ScientifiX, Inc. (“ZEO” or the “Company”) (f/k/a Organicell Regenerative Medicine, Inc.) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). Effective February 20, 2024, we further amended our Articles of Incorporation to assume our current name, Zeo ScientifiX, Inc.

The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).

The Company has recently developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications. During November 2024, the Company announced that it was launching the first planned collaborative topical product with its affiliate Exotropin LLC; “ZEO HAIR GROW™ Powered By Exotropin™”.

For the six months ended April 30, 2025 and 2024, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers.

Effective November 28, 2023, we implemented a one-for-200 reverse stock split (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the Reverse Split ratio of one-for-200 and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All share and per share amounts referenced herein give effect to the Reverse Split as of the earliest period presented.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited and include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. In the opinion of management, the condensed unaudited consolidated financial statements contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of April 30, 2025, the results of its operations for the three and six months ended April 30, 2025 and 2024 and the cash flows for the six months ended April 30, 2025 and 2024. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities Exchange Commission, although we believe that the disclosures made are adequate to make the information not misleading. These unaudited consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended October 31, 2024 filed with the Securities and Exchange Commission.

All amounts presented have been rounded to the nearest thousand except share amounts, share prices and earnings per share.

Concentrations of Risk

Credit Risk

The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At April 30, 2025, the Company did not have cash balances in one financial institution in excess of FDIC insurance coverage limits.

Major Customer

During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor and $341,000 (15.2%) and $228,000 (10.2%) to two individual medical practices.

During the six months ended April 30, 2024, the Company sold products and services totaling approximately $477,000 (20.9%) to a large distributor, approximately $237,000 (10.4%) to another large distributor and approximately $311,000 (13.6%) to an individual medical practice.

The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.

Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.

Revenue Recognition

The Company follows the guidance of the Financial Accounting Standards Board (“FASB’) Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts.

The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet.

Net Income (Loss) Per Common Share

Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments.

At April 30, 2025, the Company had 3,591,721 common shares issuable upon the exercise of options and warrants (vested and unvested), 228,333 unvested restricted stock (178,333 unissued) and $725,000 of convertible debt securities that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the six months ended April 30, 2025.

At April 30, 2024, the Company had 2,644,194 common shares issuable upon the exercise of options and warrants (vested and unvested), 167,500 unvested restricted stock and $725,000 of convertible debt securities warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the six months ended April 30, 2024.

Stock-Based Compensation

All stock-based payments are recognized in the financial statements based on their fair values.

The Company periodically issues stock options and stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $11,000 and $6,000 for the three months ended April 30, 2025 and 2024, respectively and approximately $29,000 and $33,000 for the six months ended April 30, 2025 and 2024, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials.

Fair Value of Financial Instruments

The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made.

The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments.

The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.

Level one — Quoted market prices in active markets for identical assets or liabilities;

Level two — Inputs other than level one inputs that are either directly or indirectly observable such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level three — Unobservable inputs that are supported by little or no market activity and developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of convertible notes approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Segment Information

Under ASC 280, Segment Reporting, operating segments are defined as components of an enterprise where discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company has one component. Therefore, the Company’s Chief Executive Officer, who is also the CODM, makes decisions and manages the Company’s operations as a single operating segment for the manufacture and distribution of its products.

Recently Issued Accounting Pronouncements

In January 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, in November 2024, and ASU 2025-01, Clarifying the Effective Date. These 6 updates require entities to provide disaggregated disclosure of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning December 1, 2027, and is not expected to have a material impact on its consolidated financial statements and related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment’s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company’s consolidated financial condition, results of operations or cash flows. This ASU is applicable to the Company’s Annual Report on Form 10-K for the fiscal year ending October 31, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statements, including their presentation and related disclosures.

NOTE 3 – GOING CONCERN

The unaudited accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred net losses of $2,634,000 for the six months ended April 30, 2025 and used $78,000 of cash in operating activities during that period. In addition, the Company had a stockholders’ deficit of $2,100,000 at April 30, 2025.

United States Food and Drug Administration (“FDA”) regulations which were announced in November 2017 and which became effective in May 2021 require that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s.

As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the Company’s ability to process, sell and distribute the products currently being produced or developed in the future are not restricted; and/or (b) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all.

In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (a) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines; (b) the Company will be able to establish a stabilized source of revenues, including efforts to expand sales internationally and the development of new product offerings and/or designations of products; (c) obligations to the Company’s creditors are not accelerated; (d) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations; (e) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and ongoing safety and efficacy of its products; and/or (f) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources.

There is no assurance that the products we currently produce will not be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s and/or the Company will be able to complete its revenue growth strategy. There is no assurance that the Company’s research and development activities will be successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues.

If revenues do not increase and stabilize, if the Company’s ability to process, sell and/or distribute the products currently being produced or developed in the future are restricted, and/or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws.

The independent auditor’s report dated January 29, 2025 included in our Annual Report on Form 10-K for the year ended October 31, 2024 included an explanatory paragraph as to the Company’s ability to continue as a going concern. As of April 30, 2025, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

NOTE 4 – INVENTORIES

Schedule of inventories
	April 30, 2025		October 31, 2024
Raw materials and supplies	$	132,000	$	164,000
Finished goods		103,000		68,000
Total inventories	$	235,000	$	232,000

NOTE 5 – PROPERTY AND EQUIPMENT

Schedule of property and equipment
	April 30, 2025			October 31, 2024
Finance lease equipment	$	138,000		$	13,000
Manufacturing equipment		757,000			757,000
		895,000			770,000
Less: accumulated depreciation		(325,000	)		(292,000	)
Total property and equipment, net	$	570,000		$	478,000

Depreciation expense totaled $16,000 and $19,000 for the three months ended April 30, 2025 and 2024, respectively.

Depreciation expense totaled $34,000 and $38,000 for the six months ended April 30, 2025 and 2024, respectively.

NOTE 6 – EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY


	April 30, 2025			October 31, 2024
Equity in non-marketable securities	$	145,000			145,000
Reserve on carrying value of investment in non-marketable securities	$	(145,000	)		(145,000	)
Equity in non-marketable securities	$	-			-

As of April 30, 2025 and October 31, 2024, the Company invested $145,000 in the non-marketable equity securities of Exotropin (“Exotropin”), a privately-held skin-care formulator in an effort to accelerate the Company’s development of expertise with respect to the skincare industry and the potential supply of the Company’s products in future formulations.

As of April 30, 2025 and October 31, 2024, the Company has recorded total reserves against the carrying value of its investment of Exotropin of $145,000, based on the limited financial history of Exotropin to date and the lack of any information to ascertain the fair value of Exotropin.

During November 2024, the Company received a capital call notice from Exotropin, in which the Company’s pro-rata share was $126,000 (“November Capital Call”). The Company has yet committed to participating in the November Capital Call. If the Company does not elect to participate, its interest in Exotropin would be reduced to approximately 5.6% based on all other members fully participating in the November Capital Call.

Sales Representative Agreement

During November 2023, the Company and Exotropin entered into a Sales Representative Agreement (“Sales Agreement”) in connection with the Company’s efforts to expand the use of its proprietary products for a variety of topical use applications. In connection with the Sales Agreement, the Company will receive commissions on the net sales value of Exotropin products that are sold to pre-approved retailers, wholesale distributors, private label customers and direct to consumer customers which were introduced to Exotropin by the Company of 10%, 5%, 10% and 15%, respectively.

In addition, under the terms of the Sales Agreement, the Company and Exotropin have co-developed a new product offering for the treatment of hair loss to be sold through physicians. This first collaborative topical product “ZEO HAIR GROW™ Powered By Exotropin™” was launched in November 2024 (“Collaboration”). Under the terms of the Collaboration, the Company will be responsible for the sales and marketing of the products and the parties will share equally in the net profits from the sales of the products after reimbursement of all direct cash costs incurred by either party in connection with the development, supply and sale of the products.

For the three months ended April 30, 2025 and 2024, $19,000 and $53,000, respectively, of commissions were earned under the Sales Agreement. For the six months ended April 30, 2025 and 2024, $51,000 and $87,000, respectively, of commissions were earned under the Sales Agreement. The commissions earned under the Sales Agreement are reflected in other income in the unaudited consolidated financial statements.

NOTE 7 – FINANCE LEASE OBLIGATIONS

During April 2025, the Company entered into a lease agreement for certain lab equipment in the amount of $125,000 (“Lease Agreement”). The Lease Agreement was accounted for as a finance lease obligation. Under the terms of the lease agreement, the Company is required to make 60 equal monthly payments of $1,600 plus applicable sales taxes. Under the lease agreement, the Company has the option to acquire all of the leased equipment for a nominal amount upon termination of the lease. The annual interest rate charged in connection with the lease is 2.7%. Lease payments and depreciation of the leased equipment began during June 2025, the date that the lease equipment was installed and became operational. The leased equipment is being depreciated over their estimated useful lives of 15 years beginning from the date it became operational. As of April 30, 2025, $92,000 was due under the lease through 2030, of which $14,000 is current.

NOTE 8 – RELATED PARTY TRANSACTIONS

For the three months ended April 30, 2025 and 2024 and the six months ended April 30, 2025 and 2024, the Company sold a total of approximately $24,000, $52,000, $24,000 and $82,000, respectively, of product to a management services organization (“MSO”) that provides administrative services and contracts for medical supplies for several medical practices, of which Dr. George Shapiro, the Company’s Chief Medical Officer and a member of the board of directors has an indirect economic interest in the parent company that owns the MSO.

NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES


	April 30, 2025		October 31, 2024
Accrued payroll related liabilities	$	667,000	$	667,000
Lab equipment and supplies payables		88,000		54,000
Clinical trial and research payables		634,000		648,000
Legal fees payable		175,000		127,000
Other professional fees payable		133,000		119,000
Accrued commissions payable		21,000		18,000
Construction payables		9,000		9,000
Other payables and accrued expenses		158,000		77,000
Total Accounts Payable and Accrued Expenses	$	1,885,000	$	1,719,000

NOTE 10 – NOTES PAYABLE

Schedule of notes payable
	April 30, 2025			October 31, 2024
Convertible Promissory Notes	$	725,000		$	725,000
Unamortized discount		(33,000	)		(45,000	)
Total Notes Payable	$	692,000		$	680,000

Convertible Promissory Notes

The Convertible Promissory Notes are due September 30, 2026. Interest on the Convertible Promissory Notes is 8.0 % payable annually and together with the principal amount on the maturity date.

The Convertible Promissory Notes may be prepaid by the Company, in whole, but not in part, at any time prior to the Maturity Date, subject to payment of a premium of 10%, provided that the Company gives the holders fifteen (15) business notice prior to prepayment, during which period, Investors may elect to convert the Notes and accrued but unpaid interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Note) for twenty consecutive (20) trading days ending on the date the Company gives the holders of the Convertible Promissory Notes notice of prepayment.

Holders of the Convertible Promissory Notes will have the right, at any time during the period commencing on April 1, 2024 and ending on the earliest to occur of the Maturity Date, the date of a Prepayment or the date of an automatic conversion, to convert the Convertible Promissory Note in whole, but not in part, and accrued interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Convertible Promissory Note) for twenty consecutive (20) trading days ending on the date the investor gives the Company a notice of conversion, subject to a minimum conversion price of $6.00 per Share.

In addition, the Convertible Promissory Notes and accrued but unpaid interest thereon will automatically convert into Shares in the event that prior to the Maturity Date, the Company consummates a “Qualified Financing” or a “Qualified Sale” (as defined in the Convertible Promissory Note) at a conversion price equal to 80% of the offering price of Shares sold in the Qualified Financing or 80% of the purchase price per Share to be received by stockholders following consummation of a Qualified Sale.

In connection with the issuance of the Convertible Promissory Notes, the Company recorded a discount in the amount of $72,000. The discount is being amortized over the term of Convertible Promissory Notes. For the three months ended April 30, 2025 and 2024, $5,000 and $5,000, respectively, of the discounts recorded in connection with the issuance of the Convertible Promissory Notes have been amortized. For the six months ended April 30, 2025 and 2024, $12,000 and $12,000, respectively, of the discounts recorded in connection with the issuance of the Convertible Promissory Notes have been amortized.

At April 30, 2025, the unamortized debt discount recorded in connection with the issuance of the Convertible Promissory Notes was $33,000.

NOTE 11 – CAPITAL STOCK

Series C Preferred Shares

During December 2024, Skycrest requested that it be allowed to transfer the 50 shares of Series C Preferred Shares of the Company it holds to Ian T. Bothwell, the Company’s Interim Chief Executive Officer and Chief Financial Officer (“Transfer”). In December 2024, the Board of Directors of the Company approved the Transfer and the Transfer was completed.

Common Stock

On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to affect a reverse split of our issued and outstanding common stock on a one-for-two-hundred basis. The reverse stock split was effective with FINRA on November 28, 2023 (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. All share and per share amounts have been retroactively adjusted to reflect the split as if it occurred at the earliest period presented.

2021 Plan

In September 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). The 2021 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares (an “Award”) to any person who is an employee or director of, or consultant to the Company. The maximum aggregate number of shares that may be issued pursuant to all Awards was 1,250,000 shares. On June 6, 2023, the Company’s board of directors and stockholders holding a majority of the Company’s voting power, approved an increase in the number of shares of the Company’s common stock reserved for issuance under the Company’s 2021 Plan from 1,250,000 shares to 2,500,000 shares.

The 2021 Plan is administered by (a) the board of the directors of the Company; or (b) a committee designated by the board, which Committee shall be constituted in such a manner as to satisfy the applicable laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such committee shall continue to serve in its designated capacity until otherwise directed by the board. The board of directors may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company’s shareholders to the extent such approval is required by applicable laws.

As of April 30, 2025, a total of 1,455,482 Awards (net of 1,218,647 Awards redeposited for future issuance) that have been awarded under the 2021 Plan remain issued and outstanding.

Restricted Stock Awards

Effective February 1, 2025, in connection with an agreement with an independent sales representative (“Representative”), the Company agreed to grant the Representative 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period beginning with the first month subsequent to the monthly period that the Representative has generated a cumulative amount of sales for the Company in excess of $500,000 (“Sales Milestone”). Upon a termination of the Agreement for cause or the failure of the Representative to achieve the Sales Milestone during the 1^st year of the Agreement, all unvested shares as of such time shall be forfeited (except in the case of a sale of the Company). In addition, the Representative will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Representative in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated by the Company at any time upon 30 days written notice for failure of Representative to meet sales targets, to be solely determined by the Company. The fair value of the shares as of the date of grant was $104,000. The Company will amortize $104,000 of stock-based compensation expense over the remaining term of the agreement beginning when the Representative has met the vesting conditions.

A summary of unvested restricted stock activity for the six months ended April 30, 2025 are presented below:

Schedule of non vested share activity
	Number of Non-vested Shares			Fair Value			Weighted- Average Grant Date Value
Non-vested Shares at October 31, 2024		185,000		$	257,000		$	1.79
Non-vested Shares Granted		40,000		$	105,000		$	2.62
Vested		(46,667	)	$	(54,000	)	$	-
Expired/Forfeited		-		$	-		$	-
Non-vested Shares at April 30, 2025		178,333		$	308,000		$	1.98

The Company recorded a total of $22,000 and $54,000 of stock-based compensation expense based on the grant date fair value of these shares during the three months and six months ended April 30, 2025, respectively.

There was approximately $308,000 of unamortized compensation associated with unvested stock grants outstanding as of April 30, 2025 that will be amortized over their respective remaining service periods.

NOTE 12 – STOCK OPTIONS AND WARRANTS

The Company has issued option securities under its Incentive Plan and warrants entitling the holder to purchase shares of its common stock at specified prices and for specified exercise periods.

Options:

A summary of the Company’s option activity for the six months ended April 30, 2025 is presented below:

Schedule of stock options and warrants
	Number of Shares			Weighted- average Exercise Price		Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at October 31, 2024		963,288		$	2.94		8.07	$	-
Granted		76,341		$	2.99		5.00	$	-
Exercised		-		$	-		-	$	-
Expired/Forfeited		(7,147	)	$	4.50		4.10	$	-
Outstanding at April 30, 2025		1,032,482		$	2.93		7.39	$	1,000
Exercisable at April 30, 2025		614,620		$	3.15		7.46	$	1,000

During the six months ended April 30, 2025, under its Incentive Plan, the Board approved the granting of options to certain employees to purchase 11,341 shares of its common stock. The options vest annually over 3 years, expire five years from the date of grant and had an aggregate fair value of $39,000 at the date of grant.

The Company valued the options using a Black-Scholes option pricing model with the following assumptions:


Exercise prices	$	4.50
Expected dividends		-
Expected volatility		152	%
Risk free interest rate		4.36	%
Expected term of options		5.0 years

During the six months ended April 20, 2025, the Board approved the granting of options to purchase 65,000 shares of its common stock to Dr. Everts, Chief Science and Technology Officer of the Company and Mr. Ron Borsheim, Chief Sales Officer of the Company in accordance with their employment agreements. The options are exercisable until the fifth anniversary date of the date of issuance and had an aggregate fair value of $177,125. The options vest over a five-year periods. The Company valued the options using a Black-Scholes option pricing model with the following assumptions:

Schedule of assumptions used
Exercise prices	$2.50 - $3.08
Expected dividends	-
Expected volatility	149% - 151	%
Risk free interest rate	3.91% - 4.34	%
Expected term of options	5.0 years

Options totaling 7,147 that were previously issued to certain employees that were no longer employed by the Company as of April 30, 2025, were forfeited.

During the three months ended April 30, 2025 and 2024, the Company amortized $265,000 and $273,000, respectively, of stock compensation costs associated with options vesting during the period.

During the six months ended April 30, 2025 and 2024, the Company amortized $514,000 and $519,000, respectively, of stock compensation costs associated with options vesting during the period.

There was approximately $978,000 of unamortized compensation associated with options outstanding as of April 30, 2025 that will be amortized over their respective remaining service periods.

Warrants:

A summary of the Company’s warrant activity for the six months ended April 30, 2025 is presented below:

Schedule of warrant activity
	Number of Shares		Weighted- average Exercise Price		Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at October 31, 2024		2,559,239	$	3.77		7.97	$	-
Granted		-	$	-		-	$	-
Exercised		-	$	-		-	$	-
Expired/Forfeited		-	$	-		-	$	-
Outstanding at April 30, 2025		2,559,239	$	3.77		7.47	$	4,000
Exercisable at April 30, 2025		2,228,684	$	3.98		7.22	$	4,000

During the three months ended April 30, 2025 and 2024, the Company amortized $810,000 and $527,000, respectively, of stock compensation costs associated with warrants vesting during the period.

During the six months ended April 30, 2025 and 2024, the Company amortized $1,620,000 and $1,054,000, respectively, of stock compensation costs associated with warrants vesting during the period.

There was approximately $1,385,000 of unamortized compensation associated with warrants outstanding as of April 30, 2025 that will be amortized over their respective remaining service periods.

All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations.

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Joint Venture with BioXtek, LLC

On February 4, 2025, the Company entered into a Binding Memorandum of Understanding (“Binding MOU”) with BioXtek, LLC, a Florida limited liability company (“BioXtek”) setting forth the terms of a joint development, manufacturing, marketing and funding arrangement to be entered into by the Company and BioXtek in various phases (“Joint Venture”).

The Joint Venture contemplates, among other matters:

●

The Company relocating its current operations located at Nova Southeastern University in Davie, Florida, to sublet space at the BioXtek Facility in Pompano Beach, Florida expected to be completed by May 31. 2025, which will include administrative, laboratory (research and development) and clean room (tissue processing) space, as well as shared common area space;

●

The Company and BioXtek establishing a jointly-owned (50/50) special purpose entity (the “SPE”), to pursue the development and commercialization of agreed upon products including membrane patches that are used primarily in the wound care and surgical markets (“Membrane Products”), and conduct and complete required clinical trials and/or studies for mutually agreed upon indications and products with the goal of the SPE obtaining FDA approval in the form of a BLA license or other designated license required by the FDA to permit the SPE to commercialize the product(s) (the “SPE Business”). The Company and BioXtek have agreed to use their respective commercially reasonable efforts to secure funding for the SPE Business. In addition, under the terms of the Joint Venture, the SPE will become the exclusive distributor (subject to certain agreed upon exceptions for current customers of BioXtek) of the Membrane Products;

●

In addition, as a result of the Joint Venture, the parties intend to seek operating efficiencies as a result of overlap in their respective operations, including administrative, laboratory and research personnel and research and manufacturing assets used in connection with the SPE Business and their respective individual businesses;

The Company and BioXtek have agreed to work in good faith towards the preparation, authorization, execution and delivery of a series of definitive agreements documenting the Joint Venture on the terms set forth in the Binding MOU and including other terms and conditions typical and customary for agreements of this type and nature. However, in the event the Parties fail to agree upon and execute such definitive agreements, then the Binding MOU shall govern the terms of the Joint Venture.

Deferred Revenue

Amounts received by the Company for products that have yet to be delivered to the customers as of April 30, 2025 and October 31, 2024 are reflected in the Company’s balance sheet as deferred revenues and were comprised of the following:

Schedule of deferred revenue
	April 30, 2025		October 31, 2024
Advances On Future Purchases Of Inventory	$	483,000	$	608,000
Sales To Customers Not Yet Delivered		373,000		276,000
Total Deferred Revenue	$	856,000	$	884,000

Employment Agreements

Dr. Peter A. M. Everts, Ph.D.

Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“Dr. Everts”) was appointed the Company’s Chief Scientific and Technology Officer. Dr. Everts’ employment agreement provides for a base salary of $220,000 for the first year and $235,000 per annum for each subsequent year it is in effect, subject to adjustment of up to $15,000, in the event certain compensation under a consulting agreement which Dr. Everts is party to with a non-affiliated third party is not paid. In connection with the employment agreement, Dr. Everts was granted an option under the 2021 Plan to purchase 25,000 shares of our common stock at a price of $3.05 per share (fair market value on the date of grant) (“Everts Option”). The Everts Option vests 50% on the one-year anniversary of the effective date of the employment agreement and 50% on the second anniversary, contingent upon Dr. Everts’ continued employment with the Company and to the extent vested, expires five years from the date of grant.

Dr. Everts may also be paid a performance bonus to the extent earned, based on criteria established by the Company’s Board of Directors, and may be eligible to participate in the employee benefit plans maintained by the Company and generally applicable to other senior executives of the Company.

Dr. Everts’ employment with the Company is “At Will” meaning that his employment with the Company and his employment agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Agreement). Notwithstanding the foregoing, if at any time after the first ninety (90) days of the term, the Company terminates Dr. Everts’ employment without Cause or Dr. Everts terminates his employment with the Company for “Good Reason” (as defined in the Agreement), Dr. Everts will be entitled to receive an amount equal to one quarter (1/4) month’s salary for each successive three (3) months of employment completed as severance.

Ron Borsheim

Effective April 1, 2025, Ron Borsheim was appointed the Company’s Chief Sales Officer - Aesthetics. Mr. Borsheim’s employment agreement provides for a base salary of $225,000 and the grant of an option under ZEO’s Equity Incentive Plan (the “Incentive Plan”) to purchase 40,000 shares of our common stock at a price of $2.50 per share (fair market value on the date of grant) (the “Option”). The Option vests 50% on the one-year anniversary of the effective date of the employment agreement and 50% on the second anniversary, contingent upon Mr. Borsheim’s’ continued employment with the Company and to the extent vested, expires five years from the date of grant.

Mr. Borsheim may also be paid a performance bonus to the extent earned, based on criteria established by the Company’s Board of Directors or its Compensation Committee, and is eligible to participate in the employee benefit plans maintained by the Company and generally applicable to other senior executives of the Company.

Mr. Borsheim’s employment with the Company is “At Will” meaning that his employment with the Company and his employment agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the employment agreement). Notwithstanding the foregoing, if at any time after the first ninety (90) days of the term, the Company terminates Mr. Borsheim’s employment without Cause or Mr. Borsheim terminates his employment with the Company for “Good Reason” (as defined in the employment agreement), Mr. Borsheim will be entitled to receive an amount equal to one quarter (1/4) month’s salary for each successive three (3) months of employment completed as severance.

Mr. Borsheim’s employment agreement contains customary confidentiality, non-competition and non-solicitation covenants.

Legal Matters

Dr. Golub

On November 19, 2024, Howard Golub, M.D., the Company’s former Chief Science Officer (“Plaintiff”), filed a complaint in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida against the Company, alleging a breach of contract as a result of the Company’s failure to pay Plaintiff severance in the amount of $150,000 in connection with the non-renewal of the Plaintiff’s employment agreement with the Company. Plaintiff is demanding judgment in the amount of $150,000 plus interest and attorney’s fees. The Company is currently exploring its legal options and intends to vigorously defend against the lawsuit.

Other

In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

NOTE 14 – OTHER INCOME

Schedule of other Income
	Three Months Ended April 30,
	2025		2024
Other income (expense)
Resolution and settlement of long outstanding payables		-		130,000
Commissions on sales of Exotropin products		19,000		53,000
Other		5,000		2,000
Total	$	24,000	$	185,000


	Six Months Ended April 30,
	2025		2024
Other income (expense)
Resolution and settlement of long outstanding payables		-		153,000
Commissions on sales of Exotropin products		51,000		87,000
Proceeds from insurance claim		-		89,000
Other		5,000		5,000
Total	$	56,000	$	334,000

NOTE 15 – SUBSEQUENT EVENTS

Grant of Unvested Restricted Common Stock

On May 8, 2025, the Company entered into an agreement with a non-affiliated consultant (the “Consultant”) to advise the Company on strategic communication investor relation programs (“Consulting Agreement”). In connection with the Consultant Agreement, the Company granted the Consultant 100,000 shares of common stock (“Shares”) and warrants to purchase an additional 500,000 shares of common stock (the “Warrants”). 50,000 of the Shares vested upon execution of the Consulting Agreement and the remaining 50% will vest on the six month anniversary of the Consulting Agreement. The fair value of the Shares as of the date of grant was $286,000. The Company will amortize the $286,000 of stock-based compensation expense over the term of the Consulting Agreement. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable on the terms provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants granted was $1,428,000. The Company will amortize $1,428,000 of stock-based compensation based on the vesting of the Warrants. The Company issued the foregoing securities pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) thereof.

On May 8, 2025, under its Incentive Plan, the Board approved the granting of options to certain employees, officers and directors to purchase 165,000 shares of its common stock. 153,000 of the options vest immediately and 12,000 of the options vest over a 4-month period, expire five years from the date of grant and had an aggregate fair value of $472,000 at the date of grant. The Company valued the options using a Black-Scholes option pricing model with the following assumptions:


Exercise prices	$	2.86
Expected dividends		-
Expected volatility		148	%
Risk free interest rate		4.00	%
Expected term of options		5.0 years

On May 8, 2025, the Company awarded warrants to purchase 55,000 shares of our common stock to Greyt Ventures, LLC, a principal shareholder of the Company in consideration of consulting services rendered to the Company. The warrants are fully vested as of the award date and are exercisable for a period of five (5) years from the award date at an exercise price of $2.86 per share.

Effective May 23, 2025, in connection with an agreement with a second consultant (“Second Consultant”), the Company agreed to grant the Second Consultant 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period commencing on the date that sales obtained by the Company from customers introduced by Second Consultant exceed $400,000 (“Milestone”) and provided that the Milestone is achieved by December 31, 2025. Upon termination of the agreement for any reason, any unvested stock shall be forfeited. In addition, the Second Consultant will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Representative in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated by the Company at any time by either party upon 30 days written notice. The fair value of the shares as of the date of grant was $124,000. The Company will amortize $124,000 of stock-based compensation prorata over the vesting period.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Business Overview

We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).

To date, the Company has obtained certain Investigational New Drug (“IND”), emergency IND (“eIND”) approvals from the FDA, including applicable Institutional Review Board (“IRB”) approvals which authorized the Company to commence clinical trials or treatments in connection with the use of Zofin™ and PPX™ and related treatment protocols. The Company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available. The ability of the Company to succeed in these efforts is subject to among other things, the Company having sufficient available working capital to fund the substantial costs of completing clinical trials, which the Company currently does not have, and ultimately, obtaining approval from the FDA.

Current FDA guidance requires that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue-based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”).

We have not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products we currently produce would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. However, we do not believe that our products fall within these guidelines and intend to vigorously defend against any adverse interpretation by the FDA on the classification of our products that may be deemed as falling under this defined regulation, if any. Notwithstanding the foregoing, we are undertaking efforts on an ongoing basis to mitigate any potential risks associated with an adverse ruling by the FDA and the subsequent limitations on our ability to continue to generate revenues from the sale of our products in the United States until the Company obtains the required licenses. The efforts include continuing with clinical trials, expanding sales internationally and developing new product offerings and/or designations of products that would not fall under these regulations.

All share and per share amounts referenced herein give effect as of the earliest period presented to a 200 for one reverse stock split implemented effective November 28, 2023.

The following discussion of the Company’s results of operations and liquidity and capital resources should be read in conjunction with our condensed unaudited financial statements and related notes thereto appearing in “Item 1. Financial Statements” of Part I of this Report.

Results of Operations

Three months ended April 30, 2025 as compared to three months ended April 30, 2024

Revenues. Our revenues for the three months ended April 30, 2025 were $1,149,000, compared to revenues of $1,131,000 for the three months ended April 30, 2024. The small increase in revenues during the three months ended April 30, 2025 of $18,000 or 1.6% from the three months ended April 30, 2024, was due to increases in revenues associated with its PPX™ service platform during the three months ended April 30, 2025, compared with the three months ended April 30, 2024, partially offset by decreases in revenues from the Company’s allogenic aesthetic biologic products sold during the three months ended April 30, 2025, compared with the three months ended April 30, 2024.

The revenues and percentage of overall unit sales derived from the Company’s higher concentration allogenic aesthetic biologic product offerings, lower concentration allogenic aesthetic biologic product offerings and its PPX™ service platform for the three months ended April 30, 2025, as compared to the three months ended April 30, 2024 are presented below:

	Three Months Ended April 30, 2025				Three Months Ended April 30, 2024				Change In Revenues & Percentage Of Overall Revenues
Higher Concentration Allogenic Aesthetic Biologics	$	335,000	29.2	%	$	639,000	56.5	%	$	(304,000	)	-26.9	%
Lower Concentration Allogenic Aesthetic Biologics	$	473,000	41.2	%	$	312,000	27.6	%	$	161,000		14.2	%
	$	808,000	70.3	%	$	951,000	84.1	%	$	(143,000	)	-12.6	%
PPX™	$	282,000	24.5	%	$	109,000	9.6	%	$	173,000		15.3	%
Other	$	59,000	5.1	%	$	71,000	6.3	%	$	(12,000	)	-1.1	%
Total	$	1,149,000	100.0	%	$	1,131,000	100.0	%	$	18,000		1.6	%

The Company attributes the decrease in revenues from higher and lower concentration allogenic aesthetic biologic products sold during the three months ended April 30, 2025, compared to the three months ended April 30, 2024 due to additional product competition in the marketplace and ongoing uncertainties surrounding the United States economy which attracted greater demand for the Company’s lower priced allogenic aesthetic biologic product offerings.

The increase in the overall unit sales associated with its PPX™ service platform was primarily due the Company’s continued sales and marketing efforts which included engaging additional sales representatives, participation in industry related conferences, sponsoring of educational webinars and from sales of PPX™ to the Company’s existing customers.

Cost of Revenues. Our cost of revenues for the three months ended April 30, 2025 was $256,000, as compared to cost of revenues of $284,000 for the three months ended April 30, 2024. The decrease in the cost of revenues for the three months ended April 30, 2025 of $28,000 or 9.9%, from the three months ended April 30, 2024, was due to the decrease of approximately $61,000 in the costs of revenues for its allogenic aesthetic biologic products sold for the three months ended April 30, 2025, as compared to the three months ended April 30, 2024, partially offset from an increase of approximately $33,000 of cost of revenues associated with its PPX™ service platform during the three months ended April 30, 2025, compared with the three months ended April 30, 2024.

The decrease in the costs of revenues for its allogenic aesthetic biologic products sold during the three months ended April 30, 2025 as compared to the three months ended April 30, 2024 was the result of sales coming from a greater ratio of lower cost units than higher cost units, partially offset from the overall increase in total units sold.

The increase in the cost of revenues associated with its PPX™ service platform during the three months ended April 30, 2025 as compared to the three months ended April 30, 2024 was the result of an increase in units sold partially offset from the reduction in the costs of revenues per unit sold.

Gross Profit. Our gross profit for the three months ended April 30, 2025 was $893,000 (77.7% of revenues), as compared to gross profit of $847,000 (74.9% of revenues) for the three months ended April 30, 2024. The increase in gross profit during the three months ended April 30, 2025 of $46,000 (5.4%) was the result of increases in the gross margins received from sales of its PPX™ service platform, partially offset from reduced gross margins received from the sale of its allogenic aesthetic biologic products.

In addition, the percentage of the Company’s revenues associated with its PPX™ service platform, which has a lower gross margin percentage as compared to the Company’s allogenic aesthetic biologic product offerings, increased to 24.5% of revenues for the three months ended April 30, 2025, as compared with 9.6% of revenues for the three months ended April 30, 2024. The percentage of the Company’s revenues associated with its allogenic aesthetic biologic product decreased to 70.3% of revenues for the three months ended April 30, 2025, as compared with 84.1% of revenues for the three months ended April 30, 2024.

General and Administrative Expenses. General and administrative expenses for the three months ended April 30, 2025 were $2,287,000, as compared with $2,411,000 for the three months ended April 30, 2024, a decrease of $124,000 or 5.1%. The decrease in the general and administrative expenses for the three months ended April 30, 2025, from the three months ended April 30, 2024, was primarily the result of (a) decreased payroll and consulting fees of approximately $97,000, (b) decreased commissions and travel costs of approximately $56,000, (c) decreased marketing related expenses of $6,000 and (d) decreased stock-based compensation costs to advisors, consultants and administrative staff totaling approximately $91,000 during the three months ended April 30, 2025, as compared to the three months ended April 30, 2024, which were partially offset by (1) increased laboratory related costs of approximately $63,000, (2) increased professional fees of approximately $19,000 and (3) increased office and insurance related expenses of approximately $39,000 during the three months ended April 30, 2025, as compared to the three months ended April 30, 2024.

The decrease in commissions and travel costs during the three months ended April 30, 2025, as compared to the three months ended April 30, 2024, was principally the result of reduced sales and a larger percentage of sales that were generated from house accounts with much lower commission costs than paid to distributors and/or independent sales representatives. The decrease in payroll related expenses during the three months ended April 30, 2025, from the three months ended April 30, 2024, was principally the result of the non-renewal of certain executive employment contracts in May 2024

Other income. Other income for the three months ended April 30, 2025 was $24,000, as compared to other income of $185,000 for the three months ended April 30, 2024, a decrease of $161,000. The decrease in other income was principally due to non-recurring income in connection with the settlement of liabilities of approximately $130,000 which occurred during the three months ended April 30, 2024 and the reduction in commissions received from sales of Exotropin products of approximately $34,000 during the three months ended April 30, 2025 as compared to the three months ended April 30, 2024.

Other expense for the three months ended April 30, 2025 was $21,000, as compared to other expense of $20,000 for the three months ended April 30, 2024. Other expense consisted of interest expense and amortization of discounts associated with the Company’s convertible promissory notes outstanding.

Six months ended April 30, 2025 as compared to six months ended April 30, 2024

Revenues. Our revenues for the six months ended April 30, 2025 were $2,239,000, compared to revenues of $2,285,000 for the six months ended April 30, 2024. The decrease in revenues during the six months ended April 30, 2025 of $46,000 (2.0%) from the six months ended April 30, 2024, was due to decreases in revenues from the Company’s allogenic aesthetic biologic products sold during the six months ended April 30, 2025, compared with the six months ended April 30, 2024, partially offset by increases in revenues associated with its PPX™ service platform during the six months ended April 30, 2025, compared with the six months ended April 30, 2024.

The revenues and percentage of overall unit sales derived from the Company’s higher concentration allogenic aesthetic biologic product offerings, lower concentration allogenic aesthetic biologic product offerings and its PPX™ service platform for the six months ended April 30, 2025, as compared to the six months ended April 30, 2024 are presented below:

	Six Months Ended April 30, 2025				Six Months Ended April 30, 2024				Change In Revenues & Percentage Of Overall Revenues
Higher Concentration Allogenic Aesthetic Biologics	$	875,000	39.1	%	$	1,458,000	63.8	%	$	(583,000	)	-25.5	%
Lower Concentration Allogenic Aesthetic Biologics	$	738,000	33.0	%	$	553,000	24.2	%	$	185,000		8.1	%
	$	1,613,000	72.0	%	$	2,011,000	88.0	%	$	(398,000	)	-17.4	%
PPX™	$	516,000	23.0	%	$	169,000	7.4	%	$	347,000		15.2	%
Other	$	110,000	4.9	%	$	105,000	4.6	%	$	5,000		0.2	%
Total	$	2,239,000	100.0	%	$	2,285,000	100.0	%	$	(46,000	)	-2.0	%

Cost of Revenues. Our cost of revenues for the six months ended April 30, 2025 was $447,000, as compared to cost of revenues of $443,000 for the three months ended April 30, 2024. The slight increase in the cost of revenues for the six months ended April 30, 2025 from the six months ended April 30, 2024, was due to the decrease of approximately $76,000 in the costs of revenues for its allogenic aesthetic biologic products sold for the six months ended April 30, 2025, as compared to the six months ended April 30, 2024, partially offset from an increase of approximately $79,000 of cost of revenues associated with its PPX™ service platform during the six months ended April 30, 2025, compared with the six months ended April 30, 2024.

The decrease in the costs of revenues for its allogenic aesthetic biologic products sold during the six months ended April 30, 2025 as compared to the six months ended April 30, 2024 was the result of sales coming from a greater ratio of lower cost units than higher cost units, partially offset from the overall increase in total units sold.

The increase in the cost of revenues associated with its PPX™ service platform during the six months ended April 30, 2025 as compared to the six months ended April 30, 2024 was the result of an increase in units sold partially offset from the reduction in the costs of revenues per unit sold.

Gross Profit. Our gross profit for the six months ended April 30, 2025 was $1,792,000 (80.0% of revenues), as compared to gross profit of $1,842,000 (80.6% of revenues) for the six months ended April 30, 2024. The decrease in gross profit during the six months ended April 30, 2025 of $50,000 (2.7%) was the result of reduced gross margins received from the sale of its allogenic aesthetic biologic products, partially offset by increases in the gross margins received from sales of its PPX™ service platform.

General and Administrative Expenses. General and administrative expenses for the six months ended April 30, 2025 were $4,439,000, as compared with $4,568,000 for the six months ended April 30, 2024, a decrease of $129,000 or 2.8%. The decrease in the general and administrative expenses for the six months ended April 30, 2025, from the six months ended April 30, 2024, was primarily the result of (a) decreased payroll and consulting fees of approximately $211,000, (b) decreased commissions and travel costs of approximately $207,000 and (c) decreased marketing related expenses of $22,000 during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024, which were partially offset by (1) increased stock-based compensation costs to advisors, consultants and administrative staff totaling approximately $227,000, (2) increased laboratory related costs of approximately $74,000 and (3) increased professional fees of approximately $16,000 during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024.

The decrease in commissions and travel costs during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024, was principally the result of reduced sales and a larger percentage of sales that were generated from house accounts with much lower commission costs than paid to distributors and/or independent sales representatives. The decrease in payroll related expenses during the six months ended April 30, 2025, from the six months ended April 30, 2024, was principally the result of the non-renewal of certain executive employment contracts in May 2024

Other income. Other income for the six months ended April 30, 2025 was $56,000, as compared to other income of $334,000 for the six months ended April 30, 2024. The decrease in other income was principally due to non-recurring income in connection with an insurance claim of $89,000 and the settlement of liabilities of approximately $153,000 which occurred during the six months ended April 30, 2024 and the reduction in commissions received from sales of Exotropin products of approximately $36,000 during the six months ended April 30, 2025 as compared to the six months ended April 30, 2024.

Other expense for the six months ended April 30, 2025 was $43,000, as compared to other expense of $47,000 for the six months ended April 30, 2024. The decrease in other expense of $4,000 during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024, was principally the result of reduced IRS interest and penalties. Other expense also consisted of interest expense and amortization of discounts associated with the Company’s convertible promissory notes outstanding which was unchanged for the six months ended April 30, 2025, as compared to the six months ended April 30, 2024.

Liquidity and Capital Resources

Cash and Cash Equivalents

The following table summarizes the sources and uses of cash for the periods stated. The Company held no cash equivalents for any of the periods presented:

	For the Six Months Ended April 30,
	2025			2024
Cash, beginning of period	$	657,000		$	1,756,000
Net cash used in operating activities		(78,000	)		(990,000	)
Net cash used in financing activities		(37,000	)		(20,000	)
Cash, end of period	$	542,000		$	746,000

During the six months ended April 30, 2025, the Company had cash used in operating activities of $78,000, as compared to cash used in operating activities of $990,000 for the six months ended April 30, 2024, a decrease in cash used of $912,000. The decrease in cash used was primarily the result of a reduction in general and administrative expenses and other income (expense) after adjusting for non-cash related activities of $78,000 and increases in cash provided from changes in operating assets and liabilities of $882,000 for the six months ended April 30, 2025, as compared to the six months ended April 30, 2024, partially offset by decreases in gross profit of $50,000 for the six months ended April 30, 2025, as compared to the six months ended April 30, 2024.

The increase in cash provided from changes in operating assets and liabilities was due to increases in accounts payable and accrued expenses and decreases in accounts receivable and prepaid expenses, partially offset from decreases in deferred revenues during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024. The reduction in general and administrative expenses and other income (expense) after adjusting for non-cash related activities was the result of reduced operating expenses associated with payroll, consulting costs and commission expenses during the six months ended April 30, 2025, as compared to the six months ended April 30, 2024.

During the six months ended April 30, 2025, the Company had cash used in financing activities of $37,000, as compared to cash used in financing activities of $20,000 for the six months ended April 30, 2024. The increase in cash used in financing activities of $17,000 was due to the increases in payments on finance leases.

Capital Resources

The Company has historically relied on the sale of debt or equity securities, the restructuring of debt obligations and/or the issuance and/or exchange of equity securities to meet the shortfall in cash to fund its operations.

Going Concern Consideration

Off-Balance Sheet Arrangements

Our liquidity is not dependent on the use of off-balance sheet financing arrangements (as that term is defined in Item 303(a) (4) (ii) of Regulation S-K) and as of April 30, 2025 and through the date of this report, we had no such arrangements.

Recently Issued Financial Accounting Standards

See Note 2 to our unaudited condensed consolidated financial statements included in this report for a discussion of recent accounting pronouncements.

Critical Accounting Policies

Our unaudited consolidated financial statements reflect the selection and application of accounting policies which require us to make significant estimates and judgments. See Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2024, “Summary of Significant Accounting Policies”.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported in accordance with the rules of the Securities and Exchange Commission (“SEC”). Disclosure controls are also designed with the objective of ensuring that such information is accumulated appropriately and communicated to management, including the chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosures.

Our Interim Chief Executive Officer and Chief Financial Officer (our principal executive, financial and accounting officer) evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) as of April 30, 2025, the end of the period covered by this report. Based on that evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. See the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, for a description of the Company’s material weaknesses in internal control over financial reporting.

Changes in Internal Controls over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended April 30, 2025, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II – OTHER INFORMATION

Item 1.

Legal Proceedings.

In addition to matters which have been resolved as reported in previous periodic Exchange Act filings, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

Item 1A.

Risk Factors.

As a “smaller reporting company” we are not required to disclose information under this Item.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

Exhibit No:		Description:
31.1*		Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer and Chief Financial Officer (filed herewith)
32.1*		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer (filed herewith)
101.INS **		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**		XBRL Taxonomy Extension Labels Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

	*	Filed herewith.
	**	Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ZEO SCIENTIFIX, INC.

	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell
		Interim Chief Executive Officer and Chief Financial Officer
		(Principal Executive, Financial and Accounting Officer)
		June 16, 2025